secwatch.observer — SEC 8-K summary
======================================

Issuer:     TransMedics Group, Inc. (TMDX)
CIK:        0001756262
Form:       8-K
Filed at:   2026-02-24T23:59:59+00:00
Accession:  0001193125-26-066953
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TransMedics Q4 revenue $160.8M (+32% YoY); net income $105.4M includes $83.8M tax benefit
--------------------------------------------------------------------------------

- Q4 revenue $160.8M (+32% YoY); full-year revenue $605.5M (+37% YoY).
- Net income $105.4M in Q4 ($2.62 diluted EPS); full-year net income $190.3M ($4.87 diluted EPS). Both include one-time tax benefit from valuation allowance release.
- U.S. OCS cases 5,139 in FY2025 (+38% YoY); owned 22 aircraft as of Dec 31, 2025.
- FY2026 revenue guidance $727M-$757M, representing 20% to 25% growth over FY2025.
- Appointed Giovanni Cecere as CCO, Amanda Sorrento as SVP HR, Matthew Forsyth as SVP GC; FDA approved OCS ENHANCE Heart and DENOVO Lung trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1756262/000119312526066953/0001193125-26-066953-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1756262/000119312526066953/tmdx-20260224.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-066953

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer